» Articles » PMID: 21922650

Natural Course of Low Risk Neuroblastoma

Overview
Date 2011 Sep 17
PMID 21922650
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma is characterized by heterogeneity of histology, biology, and clinical behavior. Most epidemiology studies are based on Western and Japanese populations; there are very few studies on neuroblastoma from Southeast Asia.

Procedure: Cases of Thai children with neuroblastoma were retrospectively reviewed to determine if the epidemiology of the disease differs from Western populations. Sixty-two cases were assembled from two pathology centers in Bangkok. Histologic prognostic category and MYCN copy number were determined.

Results: The median age at diagnosis was 2.9 years. Only 11% of cases presented at less than 1 year of age and 12% cases had low stage disease (1, 2, and 4S). The majority of tumors had unfavorable histology (48/62); this was at least partly due to the higher age at diagnosis for most patients. MYCN amplification was detected in 18/52 (35%) tumors, all in stage 3 or 4 tumors. We assigned patients to high, intermediate and low risk categories using the Children's Oncology Group risk stratification criteria. In contrast to Western studies, the majority of cases (50/59 or 85%) in our series had high risk disease.

Conclusions: Since there is no evidence to date that the biology of neuroblastoma varies by geographic region, the paucity of low risk cases in our study may reflect spontaneous resolution/differentiation of tumors that are not clinically detected. Moreover, a delay in diagnosis of intermediate risk cases could result in higher tumor burden at the time of diagnosis, increasing the proportion of high risk cases observed.

Citing Articles

Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.

Laopajon W, Takheaw N, Kotemul K, Pata S, Hongeng S, Kasinrerk W Explor Target Antitumor Ther. 2024; 4(6):1145-1156.

PMID: 38213540 PMC: 10776594. DOI: 10.37349/etat.2023.00188.


Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and Genotyping via Cell-Free Circulating Tumor DNA Profiling.

Kahana-Edwin S, Cain L, McCowage G, Darmanian A, Wright D, Mullins A Cancers (Basel). 2021; 13(13).

PMID: 34282791 PMC: 8267662. DOI: 10.3390/cancers13133365.


Management of neuroblastoma in limited-resource settings.

Van Heerden J, Kruger M World J Clin Oncol. 2020; 11(8):629-643.

PMID: 32879849 PMC: 7443833. DOI: 10.5306/wjco.v11.i8.629.


Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.

Keane S, Ameen S, Lindlof A, Ejeskar K Cell Commun Signal. 2020; 18(1):65.

PMID: 32312269 PMC: 7171851. DOI: 10.1186/s12964-020-00553-6.


Neuroblastoma of the Urinary Bladder in an Infant.

Mohamed A, Campbell-Hewson Q, Gabra H European J Pediatr Surg Rep. 2019; 7(1):e32-e35.

PMID: 31214484 PMC: 6579728. DOI: 10.1055/s-0039-1692192.